Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 10 (October)

1. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
   J Clin Oncol, 25(28): 4445-51. [Abstract] [Full-text]
2. Flying under the radar: the new wave of BCR-ABL inhibitors.
   Nat Rev Drug Discov, 6(10): 834-48. [Abstract] [Full-text]
3. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
   Clin Cancer Res, 13(19): 5876-82. [Abstract] [Full-text]
4. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
   Clin Cancer Res, 13(19): 5816-24. [Abstract] [Full-text]
5. Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein.
   PLoS Pathog, 3(9): 1281-90. [Abstract] [Full-text]
6. Effect of Prolonged c-Kit Receptor Inhibition by Imatinib Mesylate on the Uterine Contractility of Pregnant Rabbits.
   Gynecol Obstet Invest, 65(2): 108-111. [Abstract] [Full-text]
7. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
   Am J Respir Crit Care Med, 176(8): 814-8. [Abstract] [Full-text]
8. How I treat chronic myeloid leukemia in the imatinib era.
   Blood, 110(8): 2828-37. [Abstract] [Full-text]
9. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
   Blood, 110(8): 2991-5. [Abstract] [Full-text]
10. Imatinib mesylate in the treatment of hematologic malignancies.
    Expert Opin Biol Ther, 7(10): 1597-611. [Abstract] [Full-text]
11. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
    Gastric Cancer, 10(3): 145-52. [Abstract] [Full-text]
12. Future options for imatinib mesilate-resistant tumors.
    Expert Opin Investig Drugs, 16(10): 1549-60. [Abstract] [Full-text]
13. (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
    Leuk Lymphoma. [Abstract] [Full-text]
14. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: Clinical correlates and effect on imatinib mesylate treatment outcome.
    Leuk Lymphoma. [Abstract] [Full-text]
15. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors.
    Int J Clin Oncol, 12(5): 369-74. [Abstract] [Full-text]
16. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
    Int J Clin Oncol, 12(5): 327-40. [Abstract] [Full-text]
17. Sunitinib.
    Expert Opin Pharmacother, 8(14): 2359-69. [Abstract] [Full-text]
18. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
    J Bone Miner Res, 22(11): 1679-89. [Abstract] [Full-text]
19. Expression of C-kit in retinoblastoma: a potential therapeutic target.
    Br J Ophthalmol, 91(11): 1532-6. [Abstract] [Full-text]
20. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Clin Cancer Res, 13(20): 6136-43. [Abstract] [Full-text]
21. A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma.
    J Cutan Pathol, 34(11): 857-60. [Abstract] [Full-text]
22. Thymic carcinoma in a child with HIV infection.
    Pediatr Blood Cancer, 49(7): 1004-7. [Abstract] [Full-text]
23. Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
    J Neurooncol, 85(2): 217-22. [Abstract] [Full-text]
24. Analysis of surrogate markers for target-specific therapy in breast carcinomas using archival materials.
    Biomed Pharmacother, 61(9): 543-7. [Abstract] [Full-text]
25. Tyrosine Kinase Inhibitors in Pediatric Malignancies.
    Cancer Invest. [Abstract] [Full-text]
26. A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12.
    Ann Hematol, 86(12): 855-63. [Abstract] [Full-text]
27. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors.
    Ann Thorac Surg, 84(5): 1717-23. [Abstract] [Full-text]
28. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.
    Leukemia, 21(11): 2287-95. [Abstract] [Full-text]
29. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.
    Leukemia, 21(11): 2311-5. [Abstract] [Full-text]
30. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Biochem Soc Trans, 35: 1347-51. [Abstract] [Full-text]
31. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Expert Opin Pharmacother, 8(16): 2775-87. [Abstract] [Full-text]
32. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
    Oncogene, 26(49): 6989-96. [Abstract] [Full-text]
33. Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand.
    Cancer Sci, 98(12): 1949-58. [Abstract] [Full-text]
34. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
    Cancer, 110(9): 2000-6. [Abstract] [Full-text]
35. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
    Mol Cancer, 6(1): 67. [Abstract] [Full-text]
36. Autologous stem cell transplantation in chronic myeloid leukemia.
    Semin Hematol, 44(4): 252-8. [Abstract] [Full-text]
37. Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 104(5): 603-15. [Abstract] [Full-text]
38. Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.
    BMC Pharmacol, 7(1): 13. [Abstract] [Full-text]
39. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
    Leuk Res, 31(11): 1511-20. [Abstract] [Full-text]
40. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Leuk Res, 31(11): 1589-92. [Abstract] [Full-text]
41. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
    Int J Cancer, 121(12): 2808-14. [Abstract] [Full-text]
42. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Int J Cancer, 121(12): 2606-14. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.